| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085998915 |
| P356 | DOI | 10.1038/LEU.2017.187 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/leu.2017.187 |
| P698 | PubMed publication ID | 28607471 |
| P2093 | author name string | R P Gale | |
| C D Godwin | |||
| R B Walter | |||
| P2860 | cites work | CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy | Q24678297 |
| Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards | Q26744395 | ||
| Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia | Q27853019 | ||
| Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia | Q28202341 | ||
| Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation | Q28203306 | ||
| Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors | Q28250935 | ||
| Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia | Q28257174 | ||
| A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing | Q28288986 | ||
| Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
| Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization | Q28476825 | ||
| AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin | Q28484890 | ||
| Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline | Q28602637 | ||
| Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials | Q30835785 | ||
| Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence | Q33368039 | ||
| High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group | Q33373033 | ||
| Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study | Q33400617 | ||
| Liver Microvascular Injury and Thrombocytopenia of Antibody-Calicheamicin Conjugates in Cynomolgus Monkeys-Mechanism and Monitoring | Q33435647 | ||
| Novel insights on the DNA interaction of calicheamicin γ1I | Q56979491 | ||
| Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin | Q59694044 | ||
| Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials | Q60428767 | ||
| Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia | Q69157759 | ||
| Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195 | Q69602197 | ||
| Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases | Q77291669 | ||
| An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker | Q77491651 | ||
| Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia | Q78039785 | ||
| Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study | Q78039803 | ||
| Differences in CD33 intensity between various myeloid neoplasms | Q78360878 | ||
| Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells | Q79282538 | ||
| Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells | Q79444299 | ||
| Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project | Q80227949 | ||
| Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia | Q81478286 | ||
| Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia | Q83967551 | ||
| Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells | Q84220239 | ||
| Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML) | Q84469578 | ||
| Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients | Q84654758 | ||
| Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study | Q85217276 | ||
| Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial | Q87159616 | ||
| Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup | Q87370744 | ||
| The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia | Q87397188 | ||
| Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia | Q33643108 | ||
| Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. | Q33925386 | ||
| Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. | Q34172042 | ||
| Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. | Q34273609 | ||
| Siglec-mediated regulation of immune cell function in disease. | Q34314957 | ||
| Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed | Q34567322 | ||
| High-dose daunorubicin in older patients with acute myeloid leukemia | Q34612117 | ||
| Anthracycline dose intensification in acute myeloid leukemia | Q34612121 | ||
| Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia | Q34742630 | ||
| Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin | Q35029920 | ||
| Expression of cell-surface antigens in acute promyelocytic leukaemia | Q35205497 | ||
| High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation | Q35266020 | ||
| Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. | Q35837399 | ||
| International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts | Q35859212 | ||
| A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients | Q35859437 | ||
| Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. | Q35909648 | ||
| Acute myeloid leukemia stem cells and CD33-targeted immunotherapy | Q36058588 | ||
| CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia | Q36279306 | ||
| Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia | Q36498399 | ||
| Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies | Q36579087 | ||
| Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy | Q36698173 | ||
| Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group | Q36805474 | ||
| Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry | Q36829016 | ||
| The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients | Q36832124 | ||
| CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. | Q36914445 | ||
| A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia | Q36928318 | ||
| Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin | Q36932014 | ||
| CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology | Q36990425 | ||
| Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta | Q36996975 | ||
| CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. | Q37093860 | ||
| Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. | Q37512086 | ||
| Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia | Q37536546 | ||
| CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility | Q37708389 | ||
| Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy | Q37818248 | ||
| Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia | Q37910260 | ||
| Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin | Q38042401 | ||
| Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia | Q38109541 | ||
| CD33 in Alzheimer's disease | Q38132067 | ||
| The past and future of CD33 as therapeutic target in acute myeloid leukemia. | Q38210228 | ||
| Gemtuzumab ozogamicin in acute myeloid leukemia revisited | Q38215269 | ||
| Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. | Q38335120 | ||
| Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. | Q38469077 | ||
| Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells | Q39506455 | ||
| A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia | Q39541502 | ||
| Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells | Q39600826 | ||
| Circulating CD33 and its clinical value in acute leukemia | Q39719394 | ||
| Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia | Q39759008 | ||
| The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro | Q39759491 | ||
| Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo | Q39822717 | ||
| Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial | Q39964227 | ||
| Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples | Q40099768 | ||
| Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. | Q40319366 | ||
| Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study | Q40367786 | ||
| Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab | Q40413191 | ||
| Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity | Q40509797 | ||
| Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity | Q40616812 | ||
| Cleavage of cellular DNA by calicheamicin gamma1. | Q40668137 | ||
| Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia | Q40705613 | ||
| Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin | Q40842085 | ||
| Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial | Q41347785 | ||
| Sensitivity of fibroblasts derived from ataxia-telangiectasia patients to calicheamicin gamma 1I. | Q41717343 | ||
| Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia | Q41925220 | ||
| Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia | Q43591001 | ||
| Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin | Q43700140 | ||
| Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia | Q43856034 | ||
| The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison | Q44229660 | ||
| Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). | Q45997441 | ||
| Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice | Q46120171 | ||
| CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. | Q46156763 | ||
| CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. | Q46426075 | ||
| P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups. | Q47229171 | ||
| High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients | Q47929658 | ||
| Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia | Q48282609 | ||
| Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. | Q48349415 | ||
| SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. | Q50904360 | ||
| Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. | Q50923372 | ||
| Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. | Q50923400 | ||
| SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. | Q53154628 | ||
| Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. | Q53446336 | ||
| Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. | Q55035623 | ||
| P577 | publication date | 2017-06-13 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Gemtuzumab ozogamicin in acute myeloid leukemia |
| Q88376169 | A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells |
| Q59945270 | A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates |
| Q47217500 | A novel enediyne-integrated antibody-drug conjugate shows promising anti-tumor efficacy against CD30+ lymphomas |
| Q92856128 | A personalized approach to acute myeloid leukemia therapy: current options |
| Q48204144 | Advances in targeted therapy for acute myeloid leukaemia. |
| Q52647335 | Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. |
| Q64970629 | CAR-Expressing Natural Killer Cells for Cancer Retargeting. |
| Q91393716 | COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia |
| Q48154329 | Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies |
| Q64934977 | Combination of enzastaurin and ATRA exerts dose-dependent dual effects on ATRA-resistant acute promyelocytic leukemia cells. |
| Q92890055 | Elevated SPINK2 gene expression is a predictor of poor prognosis in acute myeloid leukemia |
| Q57022507 | Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2 |
| Q90369569 | FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1 |
| Q91909219 | Gemtuzumab Ozogamicin: Back Again |
| Q90438199 | Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia |
| Q55385806 | Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. |
| Q64996641 | Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. |
| Q89835052 | Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? |
| Q47221234 | New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness |
| Q64253519 | New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise |
| Q97421372 | Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia |
| Q54956859 | Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. |
| Q88548733 | Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms |
| Q90656358 | Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia |
| Q92366436 | Precision medicine for human cancers with Notch signaling dysregulation (Review) |
| Q93006056 | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
| Q61803941 | Relationship between CD33 expression, splicing polymorphism, and cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330 |
| Q64056800 | Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells |
| Q55022669 | Site-Specific Antibody Conjugation for ADC and Beyond. |
| Q104495182 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy |
| Q89767694 | The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia |
| Q92453398 | The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML |
| Q55354182 | Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. |
| Q89459516 | Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy |
Search more.